DRUG
Teduglutide
Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
Short Bowel Syndrome and Teduglutide Versus Placebo
Status
Completed
Phase
Phase 4
Enrollment
8
Locations
1
Results
Posted
Publications
1
Study summary
What the protocol is testing.
This research study was done to see what the effects are of Teduglutide on people with short bowel syndrome (SBS). Teduglutide is a synthetic medication administered as an injection, which has shown to increase intestinal blood flow, inhibit gastric secretion, increase growth of intestinal cells and increase absorption of nutrients. Teduglutide has demonstrated to decrease Total Parenteral Nutrition (TPN) requirements by 20%. Teduglutide is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. The primary hypotheses for this study were 1) that Teduglutide significantly increases the gastric emptying half time of solids when compared to placebo. 2) Teduglutide will significantly decrease the intestinal permeability and urinary excretion of lactulose when compared to placebo.
Full detailed description
Short bowel syndrome (SBS) refers to the anatomical and/or functional decrease in small intestinal absorptive capacity, mostly caused by extensive intestinal resections. The decrease in intestinal absorptive capacity leads to malabsorption causing malnutrition, dehydration and weight loss, all of which severely impact patient's quality of life. In this study, qualifying participants were assigned to 2 different treatment arms consisting of placebo or Teduglutide 0.05 mg/kg subcutaneously daily for seven days. Subsequently, participants were switched over to the alternate treatment arm for seven days, after a washout period of at least seven days. In both arms, after six days of treatment or placebo, participants underwent a series of measurements during day 7 of treatment, including 8 hour GI transit, permeability measurements by using mannitol and lactulose (0-2h, 2-8h collections), and 8 hour urine and stool collections for measurement of volume. Throughout the study participants filled out a food diary and a stool diary (number, consistency, ease of passage) every day. On day 7 of each intervention period participants arrived in the clinical research unit after having fasted for at least 8 hours. Women of childbearing potential had a pregnancy test. Participants then received their seventh dose of placebo or Teduglutide (1 dose, 1 hour before breakfast). Technetium sestamibi (99mTc) pellets were ingested in a scrambled egg, toast, and milk meal (218 kcal) to facilitate measurement of gastric transit. All subjects received a standard 550 kcal meal at 4 hours (chicken meal) after the radiolabeled meal.
Interventions
Treatment arms and agents.
DRUG
Placebo
Participants will receive placebo matching study drug, administered subcutaneously.
Timeline
From registration to results.
First posted
Mar 28, 2014
Study start
Jan 2014
Primary completion
Mar 2015
Study completion
Mar 2015
Results posted
Feb 22, 2016
Registry updated
Feb 22, 2016
Outcomes
What the study measures.
Primary outcomes
Gastric Emptying Half-Time (T1/2)
Time frame · approximately 2 hours after radiolabeled meal is ingested
The time for half of the ingested solids or liquids to leave the stomach.
Overall Gut Transit
Time frame · baseline, approximately 6 hours after ingestion of radiolabeled meal
Given the variable extent of the residual length of the small intestine and colon, the proportion emptied from the body at 6 hours was assessed as an overall estimate of the whole gut transit. The 6-hour values for intra-abdominal counts were then compared with the 100% reference values of counts (at time zero, which is immediately after ingestion of the radiolabeled meal) to determine the percentage of isotope retained in the abdomen. 100% minus the percentage of retained isotope reflected the amount emptied from the GI tract.
Secondary outcomes
Change in Small Intestinal and Colonic Permeability as Measured by Urinary Excretion of Mannitol
Time frame · baseline, approximately 2 hours and 8 hours after ingestion of radiolabeled meal
Permeability is measured through differential excretion of urine saccharides. A sugar solution (200 mg of mannitol and 1 g lactulose in 30 mL of water) was administered with the radiolabeled test meal at visits 1 and 2. Urine was collected during 0-2 and 2-8 hours. A baseline urine sample was also collected prior to ingestion of the sugars. Chemical analysis was preformed with high-speed liquid chromatography tandem mass spectrometry.
Change in Small Intestinal and Colonic Permeability as Measured by Urinary Excretion of Lactulose at 2 Hours
Time frame · baseline, approximately 2 hours after ingestion of radiolabeled meal
Permeability is measured through differential excretion of urine saccharides. A sugar solution (200 mg of mannitol and 1 g lactulose in 30 mL of water) was administered with the radiolabeled test meal at visits 1 and 2. Urine was collected during 0-2 and 2-8 hours. A baseline urine sample was also collected prior to ingestion of the sugars. Chemical analysis was preformed with high-speed liquid chromatography tandem mass spectrometry.
Change in Small Intestinal and Colonic Permeability as Measured by Lactulose/Mannitol Ratio at 2 Hours
Time frame · baseline, approximately 2 hours after ingestion of radiolabeled meal
Permeability is measured through differential excretion of urine saccharides. A sugar solution (200 mg of mannitol and 1 g lactulose in 30 mL of water) was administered with the radiolabeled test meal at visits 1 and 2. Urine was collected during 0-2 and 2-8 hours. A baseline urine sample was also collected prior to ingestion of the sugars. Chemical analysis was preformed with high-speed liquid chromatography tandem mass spectrometry.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion criteria: * Short bowel syndrome * Dependent on parenteral nutrition Exclusion criteria: * Pregnant, trying to become pregnant or lactating * Diabetes * Alcohol or drug abuse within the last year by history * Active Crohn's disease as evaluated by standard procedures employed by the investigator * History of radiation enteritis, scleroderma, celiac disease, tropical sprue, diabetes, chronic pseudo-obstruction or malignancies * Previous use of Teduglutide or potential allergies to Teduglutide or its constituents * Any hospitalization within 1 month before screening * Use of Octreotide, intravenous glutamine growth hormone or growth factors such as native Glucagon-like Peptide 2 (GLP-2) within the last 12 weeks * Infliximab or other biological agents, Azathioprine, Methotrexate, Cyclosporine, Tacrolimus, Sirolimus, should be stable for at least 8 weeks prior to baseline and remain stable during the study \- Any investigational drug within last 30 days * Diuretics and oral rehydration solutions will be required to be stable for ≥4 weeks prior to baseline evaluations and remain stable during the study * Change in dose of antimotility or secretory agents from 2 days prior to, and throughout the two phases and washout periods of the study * Use of tobacco products within the prior 1 month (since nicotine can affect permeability) * Use of NSAIDS or aspirin within the past week * Use of oral corticosteroids within the previous 6 weeks * Ingestion of artificial sweeteners such as Splenda (sucralose), Nutrasweet (aspartame), lactulose or mannitol 2 days each of the study measurement days, e.g., foods to be avoided are sugarless gums or mints and diet soda * History of pancreatitis * Primary renal impairment (estimated glomerular filtration rate (eGFR)) \<30 ml/min.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Related trials
More studies on Teduglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
Takeda · Short Bowel Syndrome
Phase 3
Recruiting
13
2026-06
Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)
International Centre for Diarrhoeal Disease Research, Bangladesh · Environmental Enteric Dysfunction
Phase 2
Not yet recruiting
55
2026-04
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Takeda · Short Bowel Syndrome
Not applicable
Active, not recruiting
250
2026-04
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
12
2026-03
TED_ORG: Study on Short Bowel Syndrome
Meyer Children's Hospital IRCCS · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
50
2026-02
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
600
2026-01
Registry for Participants With Short Bowel Syndrome
Shire · Short Bowel Syndrome
Not applicable
Active, not recruiting
1,806
2025-10
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
Assistance Publique - Hôpitaux de Paris · Short Bowel Syndrome
Phase 4
Completed
25
2025-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.